Group 1 - As of June 15, 10 A-share listed companies have released their performance forecasts for the first half of 2025, with 8 companies expecting year-on-year growth in net profit attributable to shareholders [1] - Among the companies, Zhongce Rubber Group Co., Ltd., C Innovation Technology Co., Ltd., and Shenzhen Youyou Green Energy Co., Ltd. are expected to achieve net profits exceeding 100 million yuan, with forecasts of 1.91 billion yuan, 494 million yuan, and 118 million yuan respectively [1] - Companies such as Luxshare Precision Industry Co., Ltd., Sichuan Southwest Jiaotong Railway Development Co., Ltd., C Innovation, Haiyang Technology Co., Ltd., and Anhui Guqi Wool Material Co., Ltd. are expected to see net profit growth rates exceeding 10%, with increases of 25.00%, 19.91%, 12.49%, 10.83%, and 10.73% respectively [1] Group 2 - Luxshare Precision, a leader in the high-end precision manufacturing sector, attributes its growth to a robust risk management capability and a vertical integration strategy that enhances its technological moat [2] - Zhongce Rubber is projected to achieve revenue between 20 billion to 21.4 billion yuan for the first half of 2025, reflecting a year-on-year growth of 8.00% to 15.56% due to expanded production scale [2] - Guangdong Taily Technology Group Co., Ltd. expects revenue of 584 million to 633 million yuan for the first half of 2025, with a year-on-year growth of 7.41% to 16.42%, driven by expanded sales channels and successful new product development [2] Group 3 - From a short-term perspective, positive performance forecasts can quickly reshape investor expectations and trigger adjustments in capital allocation [3] - Long-term value investment relies on the sustained fulfillment of profit growth commitments, which is crucial for steadily elevating corporate valuation [3] - Investors are advised to consider multiple factors, including corporate fundamentals, industry cycle positions, macroeconomic policy trends, and market sentiment fluctuations when constructing investment strategies [3]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 40 million to 50 million yuan in the first quarter of 2025, marking a turnaround from a loss in the same period last year, with an increase of 34395.37 million to 35395.37 million yuan compared to the previous year [1][2]. Performance Forecast - The performance forecast period is from January 1, 2025, to March 31, 2025 [1]. - The company anticipates a net profit attributable to shareholders of 44.535 million to 54.535 million yuan after deducting non-recurring gains and losses, representing an increase of 34944.80 million to 35944.80 million yuan year-on-year [2]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders was -30395.37 million yuan, and the net profit after deducting non-recurring gains and losses was -30491.30 million yuan [2]. Earnings Per Share - The earnings per share for the previous year was -0.90 yuan [3]. Reasons for Performance Improvement - The improvement in performance for the first quarter of 2025 is attributed to the stabilization and recovery of the rare earth market, increased production efforts, strict cost control, enhanced market analysis, and collaborative marketing efforts, leading to increased sales profits and a reduction in inventory impairment provisions compared to the previous year [4]. - The company’s equity investment in the Dabaoshan company has also contributed to increased profits, with the investment income recognized under the equity method rising [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：1358） 海外監管公告 附屬公司業績 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 本公司為一間於二零一一年五月十三日根據開曼群島法律註冊成立的獲豁免有限公司。本 公司的主要業務活動為投資控股。本集團主要於中華人民共和國（「中國」）從事研究及開發 （「研發」）、製造及銷售(i)高端輸液器、靜脈留置針產品、胰島素針等，(ii)血液淨化醫療器 械，及(iii)動物源性再生醫用生物材料及人體組織修復替代產品。 四川睿健醫療為一間於二零一三年八月六日在中國成立的股份有限公司，其股份在全國中 小企業股份轉讓系統掛牌交易（ 股份代碼：874652 ）。四川睿健醫療為一間醫療器械公司， 主要從事研發、製造及銷售血液淨化醫療器械。 單位：人民幣萬元 | | 二零二 ...

本公司之股東及潛在投資者應注意，該公告之中文版（公告編號：2025-003）已 於深圳證券交易所的巨潮資訊網站上公佈（http://www.cninfo.com.cn）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SKYWORTH GROUP LIMITED 創 維 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：00751） 海外監管公告 創維數字股份有限公司 2024 年度業績預告 本公告乃由創維集團有限公司（「本公司」）之董事會（「董事會」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及第13.10B條以及香 港法例第571章證券及期貨條例第XIVA部內幕消息條文（按上市規則所定義者） 而作出。 創維數字股份有限公司（「創維數字」，深圳證券代碼：000810）為一間於深圳證 券交易所A股上市公司及為本公司的一間非全資附屬公司，已公佈其2024年年度 業績預告（「該公告」）。該公告已轉載於 ...